29411-71-0

Upstream product

• 88121-26-0 2'?azido?2'?deoxy?3',5'?O?(1,1,3,3?tetraisopropyldisiloxane?1,3?diyl)adenosine 
• 88121-20-4 3′,5′-O-(1,1,3,3-tetraisopropyldisiloxyl)-2′-O-(trifluormethylsulfonyl)adenosine 
• 69304-45-6 3',5'-O-(1,1,3,3-tetra-isopropyldisiloxane-1,3-diyl)adenosine 
• 87792-04-9 9-[2′-azido-2′-deoxy-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxyl)-β-Darabinofuranosyl]adenine 
• 69504-03-6 3',5'-bis-O-(tert-butyldimethylsilyl)-β-D-adenosine 
• 58-61-7 adenosine 
• 695183-22-3 9-((2R,3R,4S,5R)-3-azido-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-amine 
• 118525-22-7 (2R,3S,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-3-yl trifluoromethanesulfonate 
• 82870-42-6 9-<3,5-bis-O-(tert-butyldimethylsilyl)-β-D-arabinofuranosyl>adenine 
• 129835-14-9 (2R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)dihydrofuran-3,3(2H)-diol 
• 5536-17-4 arabinosyl adenine 
• 88121-25-9 9-[3′,5′-O-(1,1,3,3-tetraisopropyldisiloxyl)-2′-O-trifluormethylsulfonyl-β-D-arabinofuranosyl]adenine 
• 88121-23-7 Acetic acid (2R,3S,3aR,9aR)-2-(6-amino-purin-9-yl)-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-yl ester 
• 87792-02-7 9-[3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-β-D-arabinofuranosyl]adenine 

Relevant academic research and scientific papers

SYNTHESIS AND PROPERTIES OF OLYGOADENYLIC ACIDS CONTAINING 2'-5' PHOSPHORAMIDE LINKAGE

Olygoadenylic acids containing 2'-5' phosphoramide linkage were prepared by poly (U) template-directed condensation.Some of their properties are described.

Synthesis of non-hydrolyzable substrate analogs for Asp-tRNAAsn/Glu-tRNAGln amidotransferase

Non-hydrolyzable substrate analogs for tRNA-dependent amidotransferase, 2′- or 3′-aspartyl or -glutamyl adenosine, were synthesized from adenosine without protection of the adenine base. The hydroxyl groups of adenosine were selectively protected, followed by a series of oxidation/reductions to alter the stereochemistry. DFT calculations revealed the driving forces for the ketone hydrate formation at C-2′, but not the C-3′ carbon during the oxidation step. Subsequently, triflation and azide replacement yielded azidoadenosines, which were coupled to protected amino acids after deprotection and reduction. After global deprotection, the target substrate analogs were obtained in 2-14% overall yields from adenosine.

Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs

The present invention is directed to new nucleoside monophosphate derivatives of lipid ester residues of general formula (I) wherein R1 represents an optionally substituted alkyl chain having 1-20 carbon atoms; R2 represents hydrogen, an optionally substituted alkyl chain having 1-20 carbon atoms; R3, R4 and R5 represent hydrogen, hydroxy, azido, amino, cyano, or halogen; X represents a valence dash, oxygen, sulfur, a sulfinyl or sulfonyl group; Y represents a valence dash, an oxygen or sulfur atom; B represents a purine and/or pyrimidine base; with the proviso that at least one of the residues R3 or R5 is hydrogen; to their tautomers and their physiologically acceptable salts of inorganic and organic acids and/or bases, as well as to processes for their preparation, and to drugs containing said compounds.